Drug Topics - March 10, 2008 - (Page 85) www.drugtopics.com MARCH 10, 2008 DRUG TOPICS 85 New Products > > > Rx NEW DRUGS Flector Patch (diclofenac epolamine) 1.3% from Alpharma, www. alpharma.com is an anti-inflammatory that provides a new alternative to nonsteroidal drugs. The patch is 4 inches by 5.5 inches and contains 180 mg of diclofenac epolamine and has also demonstrated analgesic results. A combination antihypertensive Tekturna HCT (aliskiren, hydrochlorothiazide) has been approved by the FDA. The drug contains both a direct renin inhibitor and diuretic in a single tablet. The new combination tablet from Novartis, www.tekturnahct.com, will be marketed in four strengths (aliskiren/hydrochlorothiazide): 150 mg/12.5 mg, 150 mg/25 mg, 300 mg/12.5 mg, and 300 mg/25 mg. Moxatag (amoxicillin extended-release) Tablets 775 mg from MiddleBrook Pharmaceuticals, www.middlebrookpharma.com, has been approved to treat adults and children 12 and older with pharyngitis and/or tonsillitis secondary to strep throat. The company claims that its product is the only once-daily amoxicillin product approved in this country. NEW INDICATIONS Genentech, www.gene.com, has received a newly approved indication for Herceptin (trastuzumab). The drug can now be used as a single agent for the adjuvant treatment of HER2-overexpressing node-negative or node-positive breast cancer, following multi-modality anthracycline-based therapy. The drug is for IV infusion only. Abbott’s biologic Humira (adalimumab), www. humira.com, has been approved by the FDA for two more indications—the treatment of moderate to severe chronic plaque psoriasis and to reduce the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA). Adalimumab is also approved for the treatment of ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and Crohn’s disease. Mycamine (micafungin sodium), an injectable fungicidal agent, has been approved for the treatment of candidemia, acute disseminated candidiasis, candida peritonitis, and abscesses. The Astellas Pharma, www.astellas.com, drug inhibits an enzyme essential for fungal cell-wall synthesis and is available in 50- and 100-mg vials. The Asmanex Twisthaler (mometasone furoate inhalation powder), www.asmanex.com, from Schering-Plough, is now approved for the maintenance treatment of asthma as a preventative therapy in patients ages four to 11 years old. It was previously approved in patients 12 years of age and older in 220 mcg per actuation strength. The newly approved strength is 110 mcg per actuation, administered once daily in the evening. Adults with Type 2 diabetes will now be able to ADVERTISERS INDEX ACTOS (Takeda Pharmaceuticals) INSERT, 21 ALENDRONATE (Teva Pharmaceuticals USA) 7 AMITIZA (Takeda Pharmaceuticals) IBC, INSERT, 61 BYSTOLIC (Forest Laboratories) INSERT CORPORATE (Actavis US) 65 CORPORATE (Fougera) 10-11 CORPORATE (McKesson) 39 CORPORATE (McKesson) HSE3 CORPORATE (Mylan Pharmaceuticals) 9 CORPORATE (Office Of Natl Drug Control) 91 CORPORATE (Parata Systems) 3 CORPORATE (Perrigo) 55 CORPORATE (QS/1) 87 CORPORATE (ScriptPro) 35 CORPORATE (United Drugs) 23 DORIBAX (Ortho-McNeil Pharmaceutical) INSERT EVAMIST (Ther-Rx Corp.) 56-59 FLECTOR (Alpharma US Pharmaceuticals) 29-32 FLEXPEN (Novo Nordisk ) BC FLUARIX (GlaxoSmithKline) INSERT FREESTYLE LITE (Abbott Labs) 1 HALFLYTELY (Braintree Labs) 15-16 HUMALOG (Eli Lilly & Co.) 82-84 LEXAPRO (Forest Laboratories) INSERT,37 LICEMD (Combe Inc.) 27 MUCINEX (Adams Respiratory) 13 OPTIVE (Allergan) 71 OXYCONTIN (Purdue Pharma) 51-52 PEDIA-LAX (C. B. Fleet) 18-19 PRILOSEC OTC (Procter & Gamble) 47 RESTASIS (Allergan) 41-42 RX ESSENTIALS (Pharmavite) 49 THROMBIN JMI (King Pharmaceuticals) HSE11-12 ULTRAMINI (LifeScan) 5 ZADITOR (Novartis) IFC ZOSYN (Wyeth Pharmaceuticals) HSE7-9 ZYPREXA (Eli Lilly & Co.) 63 ZYRTEC (McNeil Consumer) 69 IFC-Inside front cover IBC-Inside back cover BC-Back cover http://www.drugtopics.com http://www.alpharma.com http://www.alpharma.com http://www.tekturnahct.com http://www.middlebrookpharma.com http://www.gene.com http://www.humira.com http://www.humira.com http://www.astellas.com http://www.asmanex.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.